Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$856M |
| 2 |
Meta Platforms (Facebook)
META
|
+$647M |
| 3 |
NVIDIA
NVDA
|
+$615M |
| 4 |
Berkshire Hathaway Class A
BRK.A
|
+$304M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$301M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$1.03B |
| 2 |
UnitedHealth
UNH
|
+$686M |
| 3 |
Tesla
TSLA
|
+$387M |
| 4 |
Abbott
ABT
|
+$380M |
| 5 |
Chevron
CVX
|
+$328M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.26% |
| 2 | Healthcare | 16.96% |
| 3 | Consumer Discretionary | 12.82% |
| 4 | Consumer Staples | 9.14% |
| 5 | Industrials | 9.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3351
FTC Solar
FTCI
$38.8M
| $156K | ﹤0.01% |
+4,860
| New | +$134K |
|
3352
Escalade
ESCA
$286M
| $155K | ﹤0.01% |
11,630
+1,600
| +16% | +$21.8K |
|
|
ENLC
3353
DELISTED
ENLINK MIDSTREAM, LLC
ENLC
| $154K | ﹤0.01% |
+14,547
| New | +$145K |
|
|
ICVX
3354
DELISTED
Icosavax, Inc. Common Stock
ICVX
| $153K | ﹤0.01% |
15,400
-22,100
| -59% | -$177K |
|
3355
Outdoor Holding Co
POWW
$260M
| $152K | ﹤0.01% |
71,500
+11,100
| +18% | +$21.7K |
|
|
DXYN
3356
DELISTED
Dixie Group Inc
DXYN
| $152K | ﹤0.01% |
114,000
-20,180
| -15% | -$19.4K |
|
|
HARP
3357
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $152K | ﹤0.01% |
21,360
+1,718
| +9% | +$11.9K |
|
|
SEAC
3358
DELISTED
Seachange International Inc
SEAC
| $152K | ﹤0.01% |
18,592
+4,719
| +34% | +$41.3K |
|
3359
One Stop Systems
OSS
$332M
| $151K | ﹤0.01% |
52,600
-11,914
| -18% | -$31.5K |
|
3360
Arq
ARQ
$102M
| $150K | ﹤0.01% |
80,399
-77,846
| -49% | -$129K |
|
3361
Enlivex Ltd
ENLV
$29.5M
| $149K | ﹤0.01% |
3,779
+133
| +4% | +$5.55K |
|
3362
Blue Ridge Bankshares
BRBS
$336M
| $148K | ﹤0.01% |
16,700
+4,100
| +33% | +$37.1K |
|
3363
Taysha Gene Therapies
TSHA
$1.97B
| $148K | ﹤0.01% |
224,400
-25,200
| -10% | -$18.2K |
|
|
YARW
3364
Yarrow Bioscience, Inc. Common Stock
YARW
$113M
| $148K | ﹤0.01% |
722
+210
| +41% | +$55.9K |
|
|
PRDS
3365
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
| $148K | ﹤0.01% |
81,689
+51,189
| +168% | +$93.6K |
|
3366
Torrid Holdings
CURV
$227M
| $147K | ﹤0.01% |
52,428
+31,428
| +150% | +$100K |
|
3367
Daxor
DXR
$60.7M
| $147K | ﹤0.01% |
15,321
+200
| +1% | +$2.13K |
|
|
SVRN
3368
OceanPal Inc
SVRN
$12.2M
| $147K | ﹤0.01% |
179
+172
| +2,457% | +$383K |
|
3369
Tantech Holdings
TANH
$5.05M
| $147K | ﹤0.01% |
1,391
+53
| +4% | +$5.2K |
|
|
TRVG
3370
trivago
TRVG
$367M
| $147K | ﹤0.01% |
+22,227
| New | +$142K |
|
3371
Celularity
CELU
$20.4M
| $146K | ﹤0.01% |
27,441
+19,421
| +242% | +$124K |
|
|
AIIO
3372
Robo.ai Inc
AIIO
$497M
| $146K | ﹤0.01% |
+685
| New | +$148K |
|
|
TBIO
3373
DELISTED
Telesis Bio, Inc. Common Stock
TBIO
| $146K | ﹤0.01% |
5,128
-172
| -3% | -$6.87K |
|
3374
The RealReal
REAL
$1.34B
| $145K | ﹤0.01% |
+65,300
| New | +$89.4K |
|
3375
Solid Biosciences
SLDB
$965M
| $145K | ﹤0.01% |
27,670
-11,093
| -29% | -$62.4K |
|
Similar funds
Jim Simons's Q2 2023 Portfolio in Review
As of Q2 2023, Jim Simons held 4,468 positions worth $69.4B, down 7.9% from $75.4B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Jim Simons withdrew a net $8.1B in Q2 2023, closing 599 positions and reducing 1,691 holdings. Its most notable exit was UnitedHealth, an estimated $686M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 17% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Jim Simons opened a new position in Berkshire Hathaway Class A worth $316M.
- Jim Simons's largest Q2 2023 buy was Berkshire Hathaway Class A: 611 shares worth $316M.
- Jim Simons added most to Apple in Q2 2023, an estimated $856M increase.
- Jim Simons's biggest Q2 2023 reduction was Amazon, cutting an estimated $1.03B.
- Jim Simons fully exited UnitedHealth in Q2 2023, selling an estimated $686M.
- Jim Simons's ten largest holdings make up 12% of its $69.4B portfolio in Q2 2023.
- Jim Simons opened 541 new positions and closed 599 in Q2 2023.
- Jim Simons's portfolio value fell 7.9% quarter-over-quarter to $69.4B.
Based on Renaissance Technologies's 13F filing for Q2 2023, filed 11 Aug 2023.